# Blue Jet Healthcare shares may rally 22%, says Motilal Oswal 2026-08-18T06:56:50+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 1 independent outlet Motilal Oswal has initiated coverage on Blue Jet Healthcare with a 'buy' rating and a target price of Rs 850, implying a potential upside of 22% from current levels. The brokerage believes the market is undervaluing the company's emerging opportunities and pricing it largely on its existing business only. Blue Jet Healthcare, a manufacturer of specialty chemicals and pharmaceutical intermediates, is expanding into high-growth areas such as contrast media and niche peptides. Motilal Oswal expects these new segments to drive revenue and earnings growth over the medium term, supported by strong execution and a healthy product pipeline. The stock has declined nearly 15% from its 52-week high, and the brokerage sees the current valuation as an attractive entry point for long-term investors. At the target price, the stock would trade at a price-to-earnings multiple of around 40 times estimated FY26 earnings. ## Coverage - ndtvprofit.com This story was synthesised by AI from the source linked above. Tags: Blue Jet Healthcare, Motilal Oswal, NSE Canonical: https://indianopinion.org/blue-jet-healthcare-shares-may-rally-22-says-motilal-oswal/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/blue-jet-healthcare-shares-may-rally-22-says-motilal-oswal/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes. How this brief was made: an AI model read the report linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/